16 January 2017 - Plans for NICE to recover the costs of its appraisals of drugs, medical devices and diagnostics, through charges to the companies which make them, have been put on hold until the Government completes its life sciences strategy.

NICE has been discussing the proposals with industry representative organisations since last summer.

NICE’s chief executive, Sir Andrew Dillon, said: “We have been working to create a new funding model for technology evaluation to meet the government’s challenge to drive efficiency and deliver better value. We’ve agreed with the Department of Health to wait for the Government’s life sciences strategy to be completed before we move forward with our plans.”

Read NICE press release